KCM
SYRS

Kennedy Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Kennedy Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-427,536
Closed -$2.21M – 742
2024
Q2 		$2.21M Buy
427,536
+22,622
+6% +$119K 0.05% 498
2024
Q1 		$2.17M Buy
+404,914
New +$2.8M 0.04% 505

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Kennedy Capital Management's SYRS Position: Q3 2024 in Review

Kennedy Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2024, closing a stake of 427,536 shares — an estimated $2.21M sold.

Kennedy Capital Management first reported a position in SYRS in Q1 2024 and held it in 2 quarters. The position peaked at $2.21M in Q2 2024. 65 funds tracked by Wall St. Rank hold SYRS as of Q3 2024.

  • Kennedy Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 427,536 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $2.21M.
  • Kennedy Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • Kennedy Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.21M in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Kennedy Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.